Investigational Medications Covered by this Policy
- Pegylated Interferon Lambda
About Expanded Access
Eiger is focused on developing medicines for patients with rare, life-threatening diseases. Clinical trials form the foundation of our development programs. These trials are designed to assess the safety and efficacy of investigational medicines. Participation in a clinical trial represents the best way, in a controlled setting, to gain access to an investigational medication.
Information about ongoing Eiger sponsored clinical trials can be accessed by calling 1-650-272-6138. In some circumstances, a patient with a serious or life-threatening disease may not be able to participate in a clinical trial. Seeking use of an investigational medication outside of a clinical trial is permitted by the FDA and commonly referred to as Compassionate Use or Expanded Access. Our policy at Eiger is intended to comply with U.S. Food and Drug Agency (FDA) requirements for any such use or access.
Procedure for Requesting Investigational Medication for Expanded Access
All requests should be sent via e-mail to email@example.com. All requests will be acknowledged within 5 business days of receipt.
Criteria for Evaluation
Eiger considers many factors when evaluating a request for expanded access of an investigational medicine, such as (but not limited to) the strength of the clinical data, the benefit-risk profile, the impact on the clinical development program, the phase of development, and probability and timing of regulatory approval.
A patient may be considered for expanded access to an investigational medicine based upon evaluation of the following minimum requirements (and others may apply based on the medicine and circumstances):
- The disease being treated must be life-threatening.
- There are no adequate alternative therapies or clinical trials available.
- The patient is not eligible for an Eiger-sponsored study for the therapy being requested.
- There must be adequate human data supporting use of the investigational medication in the treatment of the patient’s disease.
- Sufficient safety and efficacy data must exist for use of the medicine at the time of request. Generally, this will not occur before Phase 3.
- Sufficient information must be made available to make a benefit-risk analysis consistent with the establishment of an expanded access program.
- Sufficient clinical data is available to identify an appropriate patient-specific dose.
- A patient’s treating physician and Eiger’s senior medical representative both believe there is the potential for the patient under consideration to reasonably expect benefit from the treatment.
- Adequate supply exists to support both the ongoing Eiger clinical trials and approved expanded access, until and if product becomes commercially available.
- Expanded access will not adversely impact Eiger’s clinical development program or the regulatory approval process.
- The request must be made by the patient’s treating physician. The physician must be appropriately licensed.
- The treating physician must also agree to comply with the safety and monitoring requirements.
- Where appropriate, demonstration of efficacy and safety may be required for continued treatment.
- Any condition, in addition to those listed above, that in the opinion of Eiger, may preclude appropriate use of the investigational medicine.
- As stated, generally, the safety and efficacy data needed to grant expanded access are not available until the initiation of Phase 3 of clinical development. Given the unique nature of individual requests for compassionate use of investigational medications, even if a drug has entered Phase 3 of development there is no guarantee a request will be fulfilled.
Eiger may revise the expanded access policies at any time.
The Hutchinson-Gilford Progeria Syndrome and Progeroid Laminopathy Managed Access Program
Eiger BioPharmaceuticals, the distributor of the drug lonafarnib, is sponsoring a Managed Access Program (MAP) for eligible patients with Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) or a Progeroid Laminopathy (PL). The protocol governing this program can be viewed at ClinicalTrials.gov. The MAP study number is NCT03895528. Clinigen is the administrator of the lonafarnib MAP for HGPS and PL.
Patients or family members desiring more information about this program should speak to their doctors or contact The Progeria Research Foundation at 978-535-2594 or e-mail firstname.lastname@example.org. Patients and family members should not contact Clinigen. Clinigen is only authorized to speak with doctors.
For treating doctors with questions about the MAP, please contact Clinigen’s Medicine Access Team at +44 (0) 1932 824123 or email email@example.com. The doctor may also e-mail Eiger at ProgeriaMA@eigerbio.com or Eigeraccess@eigerbio.com.